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Disease-specific Quality of Life Assessment in
Intermittent Claudication: Review
T. Mehta, A. Venkata Subramaniam, I. Chetter and P. McCollum
Academic Vascular Unit, Hull Royal Infirmary, Hull, U.K.
Objectives: intermittent claudication (IC) is a common condition that has a major impact on the patients' quality of life
(QoL). Generic QoL instruments often lack sensitivity to detect small but clinically significant variation in QoL. Disease-
specific instruments may overcome this problem. This study aims to review various disease-specific QoL instruments
available for use in IC and make recommendations for clinical utilization based on validity, reliability and responsiveness.
Methods: a detailed literature search and extensive bibliography review of all papers relating to disease-specific QoL and IC.
Results: several disease-specific QoL instruments are available for use in patients with IC. The most notable of these are the
Claudication Scale (CLAU-S), Sickness Impact Profile ± Intermittent Claudication (SIPIC) and the VascuQoL. The
Walking Impairment Questionnaire (WIQ) is an objective measure of the patient's walking ability and not a QoL
instrument.
Conclusion: many of the questionnaires are new and have undergone only a limited validation process. More work is
required in this field before any one disease-specific QoL instrument can be recommended for use in patients with IC.
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Introduction
Life comprises of two fundamental aspects quantity
and quality. The significance of quality of life (QoL) is
embodied by the World Health Organization (WHO)
definition of health as a state a physical, social and
mental well-being and not just an absence of infirm-
ity.1 Quality of life as an outcome measure in the
management of intermittent claudication (IC) has
become increasingly important because interventions
for this condition aim to improve quality rather than
quantity of life.
Intermittent claudication (IC) is a common condi-
tion,2 which has been demonstrated to significantly
impair quality of life. Claudicants are limited not
only in their walking capacity and physical activity,
but also demonstrate substantial impairment in other
QoL domains including social functioning, emotional
and mental health.3,4 Conservative management,
exercise therapy, interventional radiology and surgery
have all been used in the treatment of IC with the
primary aim of reversing this QoL impairment.
Traditional clinical outcome measures including sub-
jective and objective walking distances, ankle pressure
measurements and blood flow characteristics have
been used to evaluate the efficacy of these treatments.
These clinical outcomes, however have demonstrated
poor correlation with QoL measures.5,6 Since improv-
ing QoL is the main aim of treatment, most present
day clinical trials include some form of QoL measure
in their outcomes. Thus QoL as an outcome is clearly
important, however, the most appropriate method of
QoL analysis is disputed.
Quality of life may be analyzed using generic or
disease-specific instruments. All QoL instruments,
prior to use in clinical practice should have acceptable
evidence of validity, reliability and sensitivity to
change. Generic instruments typically analyze global
QoL dimensions, e.g., physical, social and psycho-
logical well being or health. The main advantages of
generic QoL instruments are their availability, suitabil-
ity for use with any population or disease state and
their ability to provide a `` holistic measure'' of QoL.7
Certain generic instruments can provide a single
global score or `` health index'', which can be used in
quality adjusted life year (QALY) calculations for cost
effectiveness/utility analysis.8 The disadvantage of
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generic instruments is that they may lack sensitivity or
responsiveness to change. It may be argued that they
do not focus on the specific effects of the disease on
QoL, and thus may not detect subtle but clinically
important variations.7 In addition, generic QoL instru-
ments do not analyze symptoms unique to the disease
in question. The medical outcomes study (MOS) 36
item short form health survey (SF-36) is the most
popular generic instruments in use and has been rig-
orously tested for validity, reliability and responsive-
ness. However, when used in patients with increasing
lower limb ischaemia, no significant changes were
evident in the dimensions of emotional role, mental
health and social functioning.9 There was no signifi-
cant difference in these dimensions between mild
claudicants and age-matched controls.
Disease specific instruments analyze QoL related to
a specific disease or a group of similar disorders. They
specifically focus on the QoL domains affected by the
symptoms of the disease in question, and thus theor-
etically are more responsive.7,8 This responsiveness
may be positive (for example, improvement with
treatment) or negative (deterioration). Disease-specific
quality of life instruments, thus potentially represent
an attractive alternative/accompaniment to generic
QoL analysis. This review will analyze the various
disease-specific instruments currently available for
use in IC and make recommendations regarding the
most appropriate instrument for clinical utilization.
Disease-specific Instruments
Claudication Scale (CLAU-S)
The Claudication Scale (CLAU-S) is probably the most
extensively researched disease specific QoL question-
naire for IC. Developed in Germany in 1995,10 to
measure the effect of Naftidrofuryl (a 5HT2 receptor
antagonist) on claudicants' QoL, the original
questionnaire consisted of 80 items in nine domains.
Several items were specifically included to cover pos-
sible adverse effects of the drug. An initial validation
study undertaken in 100 German patients demon-
strated superior reliability and sensitivity compared
with Nottingham Health Profile (NHP) a generic QoL
instrument.11 Initial drawbacks to the scale were man-
aged by transforming the scoring method so that for
all domains, 0 represented the worst and 100 the best
possible QoL. Also the last 4 domains ± depression,
fatigue, vitality and anger ± were aggregated into one
domain termed `` mood''.12 This transformed 6-domain
scale was administered to 1173 German patients with
stage II claudication as part of an open post-marketing
surveillance study of Naftidrofuryl.13 The scale was
subsequently translated into French, English and
Flemish using the classical and well-accepted
forward-backward methodology14 and used in clinical
studies in France, Germany and Belgium. This
experience prompted further changes in the scale.
The number items was reduced to 47 and grouped
into five domains: daily living, pain, social life,
disease-specific anxiety and mood. Several items relat-
ing specifically to adverse effects of Naftidrofuryl
(e.g., sexual life items) were excluded. This shortened
questionnaire was found to be acceptable to patients,
took 10 min to complete and a score per domain was
calculated as the mean of the completed items of the
domain.15
International validation of CLAU-S was carried out
in 480 patients in France, Belgium, Germany and U.K.
from 1994±1996. This showed the scale to be valid,
reliable and able to discriminate between patients
with different disease states. In particular, the domains
of pain and daily living were most discriminative and
also correlated with the physician's assessment of
change in the patient's condition.16 Further, clinical
and biological variables directly or indirectly influ-
enced the various domains, such that this functional
Table 1. Disease-specific quality of life questionnaires for intermittent claudication.
Questionnaire Abbreviation Language Domains Items Best score Worst score
Claudication Scale CLAU-S English other 5 47 100 0
Walking Impairment
Questionnaire
WIQ English (American) 4 16 100 0
Sickness Impact Profile ±
Intermittent Claudication
SIPIC English other 1 1 0 12
King's College Hospital's
Vascular Quality of Life
Questionnaire
VascuQoL English other 5 25 7 1
Artemis Questionnaire ARTEMIS French 15 64 100 0
Peripheral Arterial Occlusive
Disease 86 Questionnaire
PAVK-86 German 7 86 1 4
Charring Cross Claudication
Questionnaire
± English 1 16 0 5
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impairment had an impact on the general quality of
life. This comprehensive validation procedure has also
shown that the English, French, German, Belgian and
Dutch translations are culturally and psychomet-
rically equivalent.15 Responsiveness was tested by
using the scale in a double-blind placebo controlled
study to determine the effect of naftidrofuryl on QoL
in claudicants.17 The pooled analysis of three studies
undertaken in Germany, France and Belgium included
754 patients randomised to naftidrofuryl (n 382) or
placebo (n 372). The QoL as measured by the CLAU-
S was the primary outcome measure, with claudica-
tion distance as a secondary measure of efficacy. The
baseline CLAU-S scores for each of the five domains
were very similar in the two groups. With treatment
the significant increase in claudication distance was
accompanied by a significant increase in QoL scores in
all domains except disease-specific anxiety.18
It is clear that extensive research has been per-
formed in the derivation and validation of the
CLAU-S. It is, however, inextricably linked to the
drug naftidrofuryl. This does not necessarily dilute
its status, though its use in more varied clinical trials,
perhaps involving angioplasty or exercise would sup-
port its position as an internationally acceptable
disease-specific QoL instrument for claudication.
Walking Impairment Questionnaire (WIQ)
The WIQ is among the best known of the disease-
specific questionnaires in claudication. However, it
was designed to objectively measure the walking abil-
ity of patients with peripheral arterial disease in the
community and not specifically the impact of claudi-
cation on QoL. It has been shown that both patients
and professionals estimate walking distances inaccur-
ately.19 There is often little correlation between patient
reported walking distances and the actual distance
walked by the patient.20
The WIQ was developed in Colorado, U.S.A. in 1990
and contains four questions. The first question has
two sections: section A specific for buttock or calf
claudication and section B used to evaluate other
symptoms that may limit walking ability. The second
question derives the WIQ distance score. This is cal-
culated from patients' difficulty ratings for seven dif-
ferent walking distances (ranging from inside the
home to five blocks). The third question derives the
WIQ speed score and is calculated from a four-item
scale of walking speed over one block. The fourth
question derives the WIQ stair climbing score calcu-
lated from a three-item scale of difficulty of climbing
one to three flights of stairs.21
In the original study, the WIQ distance and speed
scores were shown to correlate with treadmill walking
time in 26 claudicants without exercise-limiting co
morbid diseases (e.g. angina, heart failure and chronic
obstructive pulmonary disease). More recently, the
WIQ distance and speed scores have been validated
in a larger (n 145) more heterogeneous group of
claudicants and also in general medical patients with-
out claudication (n 65). The study also demonstrated
a high rank-order correlation between WIQ distance
and speed scores and the actual distance walked by
the patients on supervised six-minute walks and four-
minute walking velocity tests.22 Correlation between
the WIQ and ankle-brachial index (ABI) has also been
confirmed, such that on an average a 0.3 improvement
in ABI is associated with a 10.3% increase in WIQ
distance score.23
Since the WIQ attempts to differentiate claudication
symptoms from other leg symptoms that limit walking,
it has been extensively used along with other diagnos-
tic claudication questionnaires like the modified
WHO-Edinburgh questionnaire to detect the preva-
lence of claudication in the community.24,25 Peripheral
arterial disease is under reported and the WIQ has been
used to recognize its widespread existence and also to
group patients into claudication and non-claudication
symptoms.26 The WIQ has been used to objectively
measure the effect of pharmacotherapy and exercise
rehabilitation programmes on walking distances in
patients with IC.27±30 It is widely used in the U.S.A.
because it can yield a numerical answer to the question
most commonly asked to claudicants ± how far can
you walk? However, the idea of distance in terms of
blocks is essentially an American concept and may not
have universal application. Although the WIQ has
been validated to correlate with objective measures of
walking in terms of defined distances and speed,
because it does not specifically address the effect of
claudication on the patient's QoL, it is not a QoL meas-
ure and therefore should not be used for this purpose.
Sickness Impact Profile ± Intermittent Claudication
(SIPIC)
The Sickness Impact Profile (SIP) is a generic QoL
questionnaire developed in U.S.A. in the late 1970s.
It is based on sickness-related behavior and is sensi-
tive and culturally unbiased.31 It contains 136 items
describing limitations in 12 well-defined categories of
everyday life activity.32,33 Three of these categories ±
ambulation, body care and movement and mobility ±
form a physical domain. Emotional behavior, social
interaction, alertness behavior and communication
are aggregated into a psychosocial domain. The five
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remaining categories ± eating, work, sleep and rest,
home management and recreations and pastimes are
free standing. Overall, category and domain scores
may be calculated.33 This SIP generic questionnaire
has been used to describe QoL impairment in a variety
of clinical pain-related conditions such as coronary
heart disease, cancer, rheumatoid arthritis and low
back pain.
This SIP technique has been used to assess levels of
claudication-specific dysfunction. Twelve of the 136
items in the SIP questionnaire were taken to produce
an intermittent claudication (IC) specific scale called
Sickness Impact Profile ± Intermittent Claudication
(SIPIC). The 12 items in the SIPIC are extracted from
the SIP categories of ambulation, home management,
social interaction, mobility, alertness behavior and
sleep and rest. Scores represent the sum of the number
of dysfunction items endorsed and range from 0±12
(0 being the best and 12 the worst QoL).34 The SIPIC is
quick and easy to use, but the process used to extract
these items and produce this simple disease-specific
instrument is not clear. Similar modifications have
been made to the SIP to produce shorter instruments
to assess QoL impairment in head injury, low back
pain, stroke (SA-SIP30) and other conditions.35±37
The SIPIC, the generic SIP and the SIP `` ambulation''
category have been tested in 148 claudicants.
A significant reduction in all three scores was demon-
strated in claudicants with a walking capacity of less
than 70 W (W being a measure of work and not
distance).34 More recently the 12 item claudication
specific SIPIC was used along with other generic and
disease-specific questionnaires in a randomised con-
trolled trial of 253 Swedish patients with claudication
to test the efficacy of invasive therapy, exercise or
simple observation.38 Although in both the above
studies the SIPIC and the whole SIP were administered
together, the scores for a part of the whole question-
naire should not be analyzed independent of the over-
all score.39 To use parts of larger generic questionnaire
as a disease-specific measure requires independent
validation.
King's College Hospital's Vascular Quality of Life
Questionnaire (VascuQoL)
The VascuQoL is a disease specific QoL questionnaire
developed at the Vascular Surgical Unit of King's
College Hospital, London in 2000. The previously
described disease-specific measures were all designed
for claudication and did not encompass critical lower
limb ischaemia. The VascuQol was developed as a
disease-specific evaluative instrument across the
whole spectrum of chronic lower limb ischaemia,
which was responsive to within-patient change.
The questionnaire contains 25 items (questions)
subdivided into five domains: pain (four items),
symptoms (four items), activities (eight items), social
(two items), and emotional (seven items). Each ques-
tion has a seven-point response option. The responses
are simply averaged to give an overall and a domain
score ranging from 1 to 7 (1 is worst possible quality of
life and 7 is best possible quality of life).40
The questionnaire was developed in two stages
according to recommended methodology.41 In stage
one, a handful of `` expert patients'' and professionals
were used in item selection. One hundred thirty-seven
patients were then involved in item reduction based
on the item's frequency of being most troublesome to
the patient, called the `` clinical impact factor''. The
questionnaire thus formulated was pretested in
10 patients. In stage two, the validity, reliability and
responsiveness of the questionnaire was tested in
39 patients during two attendances, 4 weeks apart.
Construct validity was demonstrated by correlation
with Fontaine classification of disease severity, tread-
mill walking distances and like domains in the SF-36.
The questionnaire had a test-retest reliability of r more
than 0.90. Responsiveness was assessed by correlating
change in the questionnaire's total score and change
in the clinical indicators of lower limb ischaemia.
A similar method has been used to develop other
disease-specific quality of life questionnaires.
The VascuQol claims to be a more general disease
specific questionnaire for the entire spectrum of lower
limb ischaemia, rather than just for claudication.
Although developed using a rigorous staged proced-
ure, it is still relatively new. It has been validated in a
relatively small number of patients and further evalu-
ation is ongoing in a multicentre trial of bypass sur-
gery versus angioplasty in patients with critical limb
ischaemia.42
The ARTEMIS scale
The ARTEMIS scale is a French questionnaire
developed in 1993 specifically for use in patients
with peripheral arterial occlusive disease. It is a self-
administered questionnaire and combines a general
(SF-36) and a specific instrument. It contains 64 items
covering the 8 dimensions of the SF-36, 5 disease-
specific dimensions and two differential dimensions
(perception of health status evolution and perception
of the future). It has been validated in 177 patients
with Fontaine stage II intermittent claudication and
the results reveal that patients walking greater than
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500 m had significantly higher scores (better QoL)
than patients walking less than 500 m.43 Shortened
and complete versions of the questionnaire are avail-
able in French. The ARTEMIS questionnaire was used
in a large multicentre study of claudicants treated
with ifenprodil tartarate 20 mg, three times daily.
More than 4000 questionnaires were analysed over
12 months with good responsiveness of the question-
naire with global clinical improvement.44 However,
the ARTEMIS scale was developed in French and has
not been translated into other languages so far.
The Peripheral Arterial Occlusive Disease 86
Questionnaire (PAVK-86)
The PAVK-86 is a disease specific QoL questionnaire
developed in Germany in mid 1990. It comprises of 86
individual items assigned to 7 QoL domains: functional
status, pain, general complaints, mood, anxiety, social
life and treatment evaluation.45 It was originally tested
in 308 patients with confirmed peripheral arterial
occlusive disease (PAOD); Fontaine stages I to IV and
was found to be valid, reliable and sensitive. The results
showed that compared to a normal population, patients
with PAOD had considerably impaired QoL, and this
impairment was significantly greater in patients with
Fontaine stages III and IV disease. However, no differ-
ences in QoL were found between Fontaine stages III
and IV.46 This finding may be real, but may represent
lack of sensitivity. In another study involving 150
patients with stable intermittent claudication, the max-
imum walking distance was found to be the greatest
predictor of scores in the pain, general complaints and
functional status domains of the PAVK-86.47 The PAVK-
86 along with the SF-36 was completed by 104 patients
before and after 4 weeks treatment with a daily intra-
venous infusion of 60 mg of PGE1 (Prostavasin) and at
the end of 3 months. The significant increase in pain-
free and maximum walking distances at the end of
treatment was accompanied by significant improve-
ment in all domains of PAVK-86 measured QoL,
which was maintained at 3 months.48 Similarly, a 12-
week supervised training programme significantly
increased walking distances in 31 stage II claudicants
with a similar improvement in most of the QoL dimen-
sions measured by the PAVK-86.49 However, this QoL
questionnaire is only available in German and has not
yet been translated into other languages.
The Charing Cross Claudication Questionnaire
The Charing Cross Claudication Questionnaire is a 16-
item symptom specific questionnaire for claudication,
which was developed at the Charing Cross Hospital
in London using recommended methodology. Patients
and experts produced a pool of statements used to
itemize a self-administered symptom specific ques-
tionnaire, which was piloted in 20 patients. It was
validated in 124 stable claudicants and was found to
correlate with all the components of the WIQ and
the EuroQol, but not with ankle brachial pressure
index (ABPI) or treadmill walking distances.50 More
recently, this symptom specific questionnaire was
completed by 57 claudicants randomised to either a
once weekly-supervised exercise motivation class or
exercise advice alone.51 There was a significant fall in
the SSQ score (better QoL) in the supervised class
group compared to the advice alone group. However,
it is still a questionnaire in its infancy and its proof of
validity is more indirect through the WIQ. Moreover,
it is yet to be published in peer reviewed journals.
Conclusions
The assessment of QoL in the management of patients
with IC is crucially important. Generic measures lack
the sensitivity to detect subtle but clinically significant
differences. Disease-specific instruments potentially
have an important role to play and complement the
generic QoL instruments. The SF-36 has become the
established generic QoL instrument in patients with
vascular disease. However, there is no such clear
leader among the disease-specific QoL instruments
for IC. Many of the disease-specific instruments
described are reasonably new and have undergone
only a limited validation process.
Although none can be recommended as the gold
standard, the CLAU-S seems to have emerged as per-
haps the best option presently available. It has been
thoroughly validated and used in several trials and
the shortened version is translated for use in several
languages. However, further work regarding its
responsiveness and superiority over generic instru-
ments is required. Rather than devising alternative
disease-specific QoL questionnaires for IC, work
should concentrate on strengthening and evaluating
the existing instruments. The ultimate goal should be
to establish a disease-specific IC QoL instrument that
is valid, reliable and responsive and has demonstrable
benefits over generic instruments.
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